Reportlinker Adds Metastatic Clear Cell Renal Cell Carcinoma: Clinical Insights from a US Oncologists' Survey

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0487245/Metastatic-Clear-Cell-Renal-Cell-Carcinoma-Clinical-Insights-from-a-US-Oncologists-Survey.html

Metastatic Clear Cell Renal Cell Carcinoma: Clinical Insights from a US Oncologists' Survey

Two patient specific case scenarios that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open responses on clinical decisions. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment. Patients include:

1) Elderly patient with good prognosis metastatic clear cell carcinoma

2) Clear cell carcinoma and comorbidities

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Metastatic Clear Cell Renal Cell Cancer.

Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary5

Chapter 1: Introduction7

Table 1. Treatment Options in Renal Cell Cancer7

Chapter 2. Survey Respondent Demographics9

Table 2. Eligibility Criteria for Survey Participation9

Figure 2.1 Gender of Survey Respondents9

Figure 2.2 Years since Medical School Graduation10

Figure 2.3 Practice Settings10

Figure 2.4 Practices in NCI Cancer Centers11

Figure 2.5 Geographic Settings11

Figure 2.6 Survey Respondents by State's Renal Cell Cancer Mortality12

Figure 2.7 Number of Physicians in Practice Groups13

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen13

Chapter 3: Treatment of an Elderly Patient with Metastatic Clear Cell Renal Cell Carcinoma14

Figure 3.1 Treatment Regimen Chosen Following Surgery14

Figure 3.2 Adding Therapeutic Agents with Initial Treatment15

Figure 3.3 Treatment Decision for Medication Toxicity16

Figure 3.4 Second-Line Therapy17

Figure 3.5 Factors Influencing Treatment18

Figure 3.6 Confidence in Managing Clear Cell Renal Cell Carcinoma19

Figure 3.8 Most Important Barrier to Optimal Patient Management21

Chapter 4. Treatment of a Patient with Metastatic Clear Cell Renal Cell Carcinoma with Comorbidities23

Figure 4.1 Management of Patient with Metastatic Disease and Comorbidities23

Figure 4.2 Choice of Systemic Therapy Agent24

Figure 4.3 Test to Monitor to Evaluate Increased Fatigue with Pazopanib25

Figure 4.4 Next Systemic Treatment Choice for Progressive Disease26

Chapter 5: Summary27

Appendix A: Survey Instrument28

Companies mentioned

Novartis, Genentech/Roche, Onyx/Bayer, Pfizer, GlaxoSmithKline, Amgen

To order this report:

:

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker